Osteoporosis in patients under treatment for cancer and the possibilities for prevention and treatment;Osteoporose bij patiënten die worden behandeld wegens kanker en de mogelijkheden voor preventie en behandeling

Nederlands Tijdschrift voor Geneeskunde

Volumn 151, Issue 25, 2007, Pages 1388-1393

  Eekhoff, E M W ^a   Pinedo, H M ^a   Lips, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; GONADORELIN AGONIST; PARATHYROID HORMONE[1-34]; STRONTIUM; TAMOXIFEN; VITAMIN D;

BREAST CANCER; DENSITOMETRY; DIAGNOSTIC TEST; DISEASE COURSE; FRAGILITY FRACTURE; HUMAN; HYPOGONADISM; OSTEOPOROSIS; PROPHYLAXIS; PROSTATE CARCINOMA; REVIEW; RISK ASSESSMENT; SCREENING TEST; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; NEOPLASMS; OSTEOPOROSIS;

EID: 34447277636     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. 2003;97:545-53.
2. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol. 2006;24:872-7.
3. Angelopoulos N, Barbounis V, Livadas S, Kaltsas D, Tolis G. Effects of estrogen deprivation due to breast cancer treatment. Endocr Relat Cancer. 2004;11:523-35.
4. Carlsten H. Immune responses and bone loss: the estrogen connection. Immunol Rev. 2005;208:194-206.
5. Seeman E. Estrogen, androgen, and the pathogenesis of bone fragility in women and men. Curr Osteoporos Rep. 2004;2:90-6.
6. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev. 1994;15:275-300.
7. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570-93.
8. Dowsett M, Jacobs S, Aherne J, Smith IE. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Clin Ther. 1992;14 Suppl A:97-103.
9. Harris AL, Carmichael J, Cantwell BM, Dowsett M. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer. Br J Cancer. 1989;59:97-9.
10. Lester J, Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer. 2005;93 Suppl 1:S16-22.
11. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-2.
12. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353:2747-57.
13. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006;24:675-80.
14. Howell SJ, Johnston SR, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab. 2004;18: 47-66.
15. Kesteren P van, Lips P, Gooren LJ, Asscheman H, Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf). 1998;48:347-54.
16. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352: 154-64.
17. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol. 2003;169:2008-12.
18. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006;11:1121-31.
19. Uehara R, Suzuki Y, Ichikawa Y. Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: possible mechanism of MTX osteopathy. J Rheumatol. 2001;28:251-6.
20. Stanisavljevic S, Babcock AL. Fractures in children treated with methotrexate for leukemia. Clin Orthop Relat Res. 1977;125: 139-44.
21. Wang TM, Shih C. Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. Acta Anat (Basel). 1986;127:93-9.
22. Ratcliffe MA, Lanham SA, Reid DM, Dawson AA. Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause. Hematol Oncol. 1992;10:181-7.
23. Cohen LE. Endocrine late effects of cancer treatment. Endocrinol Metab Clin North Am. 2005;34:769-89.
24. Burk CD, Restaino I, Kaplan BS, Meadows AT. Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr. 1990;117(2 Pt 1):331-5.
25. Popp AW, Isenegger J, Buergi EM, Buergi U, Lippuner K. Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment. Eur Spine J. 2006;15:1035-49.
26. Heijckmann AC, Huijberts MS, Geusens P, Vries J de, Menheere PP, Wolffenbuttel BH. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol. 2005;153: 23-9.
27. Pols HAP, Wittenberg J. CBO-richtlijn 'Osteoporose' (tweede herziening). Ned Tijdschr Geneeskd. 2002;146:1359-63.
28. Karsh J. Diagnostic challenges in osteoporosis. Indications for bone densitometry and establishing secondary causes. Can Fam Physician. 2001;47:1244-50.
29. Moyad MA. The potential benefits of dietary and/or supplemental calcium and vitamin D. Urol Oncol. 2003;21:384-91.
30. Hoshino S, Ouchi Y. Right or wrong of the hormone replacement therapy involving osteoporosis. Clin Calcium. 2004;14:87-98.
31. Uebelhart B, Frey D, Uebelhart D. Hormone replacement therapy: what is the evidence today? Z Rheumatol. 2003;62:508-11.
32. Zidan J, Keidar Z, Basher W, Israel O. Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer. Med Oncol. 2004;21:117-21.
33. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45.
34. Uebelhart D, Frey D, Frey-Rindova P, Goerres G, Michel BA. Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium. Z Rheumatol. 2003;62:512-7.
35. McCune JS, Games DM, Espirito JL. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors. J Oncol Pharm Pract. 2005;11:37-43.
36. Duncan GG, Corbett T, Lukka H, Warde P, Pickles T. GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol. 2006;13:2962-6.
37. Ortolani S, Vai S. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages. Bone. 2006; 38(2 Suppl 1):19-22.
38. Tashjian jr AH, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006;21:354-65.
39. Lips P. Prevention of corticosteroid induced osteoporosis. BMJ. 1999; 318:1366-7.
40. Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res. 2006;443:39-47.